Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.43 |
| ▸ | RIPK3 | Q9Y572 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BUB1 | O43683 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509449 | 0.95 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11GRIN1 | |
| SCHEMBL13741471 | 0.80 | MAPK1 (0.47) | RIPK3KMT2AALDH1A1MEN1BUB1 | |
| SCHEMBL4099610 | 0.77 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11KMT2A | |
| SCHEMBL5091878 | 0.73 | TDP1 (0.53) | MAPK14MAPK13MAPK12MAPK11RIPK3 | |
| SCHEMBL5858727 | 0.73 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11RIPK3 | |
| SCHEMBL6583283 | 0.73 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11RIPK3 | |
| SCHEMBL4097997 | 0.70 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL5095878 | 0.69 | RIPK3 (0.57) | MAPK14RIPK3BUB1 | |
| SCHEMBL4466879 | 0.67 | MAPK14 (0.94) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3233018 | 0.67 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11RIPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | INCYTE CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | MAPK14 136/4885MAPK13 99/4885MAPK12 111/4885 |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | JAK1, JAK2, JAK3 | MAPK14 136/4885MAPK13 99/4885MAPK12 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.